-
EISAI TO PRESENT DATA ON ROBUST NEUROLOGY PORTFOLIO AT THE 76th AMERICAN ACADEMY OF NEUROLOGY® (AAN) ANNUAL MEETING
12 Apr 2024 18:27 GMT
… benefit."
In addition to the data being presented, Eisai … , including real-world experience.
Eisai Sponsored Industry Therapeutic Updates
… for ARIA.
Consider the benefit of LEQEMBI for the … noted a statistically significant benefit of 37% compared to …
-
Eisai on your hi-fi: Leqembi maker supports creation of Alzheimer’s podcast miniseries
12 Apr 2024 17:39 GMT
… the series with support from Eisai, talks to experts about … series is unbranded, Eisai could still benefit if it helps unblock … a band of podcasts that Eisai has supported. In Europe, … the ECtalk endometrial cancer series. Eisai also “conceptualized and funded” …
-
Amylyx Pulls ALS Drug AMX0035, Gene Therapy Shows Promise in Giant Axonal Neuropathy, Eisai Submits sBLA for New Lecanemab Dosing
06 Apr 2024 11:24 GMT
… and showed signs of therapeutic benefit among children with giant axonal … .
According to an announcement from Eisai and Biogen, the companies have …
-
Eisai Completes Submission of LEQEMBI (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease to the U.S. FDA
02 Apr 2024 22:42 GMT
… Breakthrough Therapy designations. However, Eisai was recently informed by … review. Following the guidance, Eisai submitted a request for … for the patient to benefit. Continued maintenance dosing is … the clinical and biomarker benefits with a dosing regimen …
-
BioArctic AB's partner Eisai submits sBLA for Leqembi with US FDA for treatment of early Alzheimer's disease
02 Apr 2024 08:29 GMT
… for the patient to benefit. Continued maintenance dosing is … the clinical and biomarker benefits with a dosing regimen … long-term collaboration with Eisai regarding the development and … commercialization agreement for lecanemab. Eisai is responsible for the …
-
Biogen and Eisai Fall Behind on Leqembi’s Subcutaneous BLA for Alzheimer’s
01 Apr 2024 13:23 GMT
… Ceren Demir
Biogen and Eisai on Monday announced that … However, the regulator informed Eisai that they would need a … to Monday’s announcement.
Eisai has since submitted a request … Study 201 translated to clinical benefits. Patients treated with Leqembi …
-
Eisai Completes Submission of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease to the U.S. FDA
31 Mar 2024 23:54 GMT
… treatment may prolong the benefit even after plaque is … for the patient to benefit. Continued maintenance dosing is … noted a statistically significant benefit of 37% compared to … benefits and potential of Biogen's collaboration arrangements with Eisai …
-
Continued Benefit, More Toxicity With Osimertinib-Chemo
25 Mar 2024 17:52 GMT
… chemotherapy is associated with continued benefits in previously untreated advanced EGFR … all prespecified subgroups.
Consistent Benefit but More Toxicity
The magnitude … Bristol-Myers Squibb, Roche, Pfizer, Eisai, Sanofi, BeiGene, Chugai Pharmaceutical Co …
-
Lifenet, Eisai co─develop Dementia Insurance 'be' to support early detection and treatment of dementia and MCI
23 Mar 2024 13:12 GMT
… these circumstances, Lifenet and Eisai co-developed a dementia … and treatment, by leveraging Eisai’s experience and network … brain-stimulating exercise content.
Eisai’s brain health (brain … and to increase the benefits that health care provides.…
-
EISAI TO PRESENT DATA ON LECANEMAB and OTHER ALZHEIMER'S DISEASE RESEARCH AT THE AD/PD™ 2024 ANNUAL MEETING
29 Feb 2024 03:53 GMT
… for the patient to benefit. We will continue to … scientific community."
Eisai Symposium – Defining meaningful benefits to patients, … and confirmed the clinical benefit of LEQEMBI.4,5 … noted a statistically significant benefit of 37% compared to …